Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | RBP4 | P02753 | 2/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.55 |
| ▸ | NEK2 | P51955 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546334 | 0.84 | TRPV1 (0.84) | TRPV1HSD11B1NOTUMRBP4MALT1 | |
| SCHEMBL3216080 | 0.83 | TRPV1 (0.69) | TRPV1HSD11B1EPHX2GAAHRH3 | |
| SCHEMBL27761289 | 0.83 | HSD11B1 (0.55) | TRPV1HSD11B1EPHX2GAAHRH3 | |
| SCHEMBL30582915 | 0.83 | EPHX2 (0.68) | TRPV1HSD11B1EPHX2GAAHRH3 | |
| SCHEMBL3932323 | 0.82 | TRPV1 (0.62) | TRPV1HSD11B1EPHX2GAAHRH3 | |
| SCHEMBL1253240 | 0.82 | ALDH1A1 (0.59) | TRPV1HSD11B1EPHX2GAAKDM4E | |
| SCHEMBL4546335 | 0.81 | TRPV1 (0.63) | TRPV1HSD11B1EPHX2KDM4ERBP4 | |
| SCHEMBL3095680 | 0.81 | HSD11B1 (0.76) | TRPV1HSD11B1EPHX2GAARBP4 | |
| SCHEMBL5799674 | 0.80 | NOTUM (0.65) | TRPV1RORCNOTUMRBP4CYP3A4 | |
| SCHEMBL1349136 | 0.80 | EPHX2 (0.64) | TRPV1HSD11B1EPHX2GAAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8168827-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2281823-A2 | Anti-inflammatory and analgesic piperidine derivatives | Ajinomoto Co., Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090258900-A1 | AMIDE DERIVATIVE | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7572815-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20060128755-A1 | Amide derivative | AJINOMOTO CO. INC (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| EP-1627869-A1 | AMIDE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128755-A1 | Amide derivative | NR0B1, NR0B2, NR1I3 | TRPV1 983/4885HSD11B1 117/4885RORC 227/4885 |
| US-20110059979-A1 | Piperidine/Cyclohexane Carboxamide Derivatives For Use as Vanilloid Receptor Modulators | TRPV1, CNR1, OPRM1 | TRPV1 1/4885HSD11B1 4094/4885RORC 1314/4885 |
| US-20090258900-A1 | AMIDE DERIVATIVE | NR0B1, NR0B2, NR1I3 | TRPV1 804/4885HSD11B1 149/4885RORC 215/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | TRPV1 92/4885HSD11B1 3638/4885RORC 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.